2017, Number 1
Rev Hematol Mex 2017; 18 (1)
Colunga-Pedraza PR, Colunga-Pedraza JE, Lozano-Morales RE, Garza-Acosta AC, Cantú-Rodríguez OG
PDF size: 131.63 Kb.
ABSTRACTMonoclonal antibodies are a successful therapeutic choice for a wide range of diseases, including hematological malignancies. Targeted therapy has been used in combination with other drugs or as monotherapy, proffering an important improvement in quality of life of patients and demonstrating a tolerable profile of adverse effects due to limited toxicity. Currently have been approved a large amount of monoclonal antibodies and several number of molecules are undergoing clinical evaluation. The present review sets out their application in hematological diseases.